Siemens Healthcare has announced that they have received the CE Mark of approval for their VERSANT CT/GC DNA 1.0 Assay, which allows clinicians to noninvasively test for Chlamydia and gonorrhea. The assay can test for infection in both symptomatic and asymptomatic patients from endocervical or urethral swabs, or from urine samples.
From the press release:
The VERSANT® CT/GC DNA 1.0 Assay (kPCR) uses in vitro nucleic acid amplification to detect plasmid DNA isolated from Chlamydia trachomatis (CT) and genomic DNA from Neisseria gonorrhoeae (GC). Siemens proprietary nucleic acid extraction method results in high DNA target recovery and high efficiency of target amplification.
Press Release: Siemens Introduces New Molecular Assay to Diagnose Sexually Transmitted Infections